Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.54 |
| ▸ | BACE1 | P56817 | 11/20 | 0.54 |
| ▸ | CTSD | P07339 | 4/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31347657 | 0.91 | CALCRL (0.54) | CALCRLBACE1CTSDSLC6A2RAMP1 | |
| SCHEMBL30385729 | 0.89 | NTSR2 (0.49) | CALCRL | |
| SCHEMBL30386802 | 0.88 | NTSR2 (0.49) | CALCRLBACE1CTSD | |
| SCHEMBL30242241 | 0.86 | SLC6A2 (0.47) | CALCRLBACE1CTSDSLC6A2KEAP1 | |
| SCHEMBL29733288 | 0.86 | CALCRL (0.51) | CALCRLBACE1CTSDSLC6A2RAMP1 | |
| SCHEMBL29680220 | 0.85 | CAPN1 (0.51) | CALCRLBACE1CTSDSLC6A2RAMP1 | |
| SCHEMBL31655494 | 0.85 | BACE1 (0.49) | CALCRLBACE1CTSDSLC6A2KEAP1 | |
| SCHEMBL31655493 | 0.85 | BACE1 (0.49) | CALCRLBACE1CTSDSLC6A2KEAP1 | |
| SCHEMBL31415964 | 0.85 | CAPN1 (0.48) | CALCRLSLC6A2CAPN1 | |
| SCHEMBL29531335 | 0.85 | NTSR2 (0.47) | SLC6A2CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | disclosed |